We also observed upregulated expression of genes encoding major histocompatibility complex (MHC) class I and II molecules (HLA-A, B, G, DMA) as well as genes encoding peptide transporter (Tap1), transporter-MHC interactions (TAPBP) and processor of MHC class I T cell epitopes (PSMB9) in the combined inhibitor treatment groups suggesting that combined PARP and WEE1 inhibition can increase tumour antigen presentation capabilities of TNBC (Supplementary Fig. 1f). Here, HLA-A is linked to neoplasm.